Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin + weekly paclitaxel and low-dose gemcitabine in metastatic pancreatic cancer after chemotherapy failure
2024-518205-17-00Phase 3Authorised
- Sponsor
- 1Globe Health Institute
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of napabucasin in pancreatic adenocarcinoma (PDAC), sponsored by 1Globe Health Institute. Primary endpoints: Progression-free survival (Phase II part), Safety (Phase II part) and 1 more. Planned start Nov 2024; status: authorised.
02
Drugs
napabucasin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-518205-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518205-17-00.